Comparative effectiveness and safety of the novel oral anticoagulants: Do the pivotal clinical trials point to a new paradigm?

A. C. Spyropoulos; N. A. Goldenberg; C. M. Kessler; J. Kittelson; S. Schulman; A. G.G. Turpie; N. R. Cutler; W. R. Hiatt; J. L. Halperin

doi:10.1111/jth.12005

Comparative effectiveness and safety of the novel oral anticoagulants: Do the pivotal clinical trials point to a new paradigm?

A. C. Spyropoulos
, N. A. Goldenberg
, C. M. Kessler
, J. Kittelson
, S. Schulman
, A. G.G. Turpie
, N. R. Cutler
, W. R. Hiatt
, J. L. Halperin

Research output: Contribution to journal › Letter › peer-review

13 Scopus citations

Original language	English
Pages (from-to)	2621-2624
Number of pages	4
Journal	Journal of Thrombosis and Haemostasis
Volume	10
Issue number	12
DOIs	https://doi.org/10.1111/jth.12005
State	Published - Dec 2012

Access to Document

10.1111/jth.12005

Cite this

Spyropoulos, A. C., Goldenberg, N. A., Kessler, C. M., Kittelson, J., Schulman, S., Turpie, A. G. G., Cutler, N. R., Hiatt, W. R., & Halperin, J. L. (2012). Comparative effectiveness and safety of the novel oral anticoagulants: Do the pivotal clinical trials point to a new paradigm? Journal of Thrombosis and Haemostasis, 10(12), 2621-2624. https://doi.org/10.1111/jth.12005

@article{1e5fda0026c246e8bbaa3c9ba95ea857,

title = "Comparative effectiveness and safety of the novel oral anticoagulants: Do the pivotal clinical trials point to a new paradigm?",

author = "Spyropoulos, \{A. C.\} and Goldenberg, \{N. A.\} and Kessler, \{C. M.\} and J. Kittelson and S. Schulman and Turpie, \{A. G.G.\} and Cutler, \{N. R.\} and Hiatt, \{W. R.\} and Halperin, \{J. L.\}",

note = "Funding Information: N.A.G. receives salary and research support in the form of a Career Development Award from the National Institutes of Health, National Heart, Lung and Blood Institute, and salary support through pharmaceutical industry sponsored research from CPC Clinical Research. Funding Information: W.R.H. is President of CPC Clinical Research. He receives support from grants provided by the National Institutes of Health and from the pharmaceutical industry for sponsored research initiatives, partial salary support through research grants provided to CPC Clinical Research and the University of Colorado, as well as fees from the U.S. Food and Drug Administration as a Special Government Employee for several advisory committees. He provides consulting services to the pharmaceutical industry though CPC Clinical Research. Current relationships include GlaxoSmithKline, sanofi‐aventis, Kowa, Portola, TheraVasc, AstraZeneca, Pluristem and Zona. ",

year = "2012",

month = dec,

doi = "10.1111/jth.12005",

language = "English",

volume = "10",

pages = "2621--2624",

journal = "Journal of Thrombosis and Haemostasis",

issn = "1538-7933",

publisher = "Elsevier B.V.",

number = "12",

}

TY - JOUR

T1 - Comparative effectiveness and safety of the novel oral anticoagulants

T2 - Do the pivotal clinical trials point to a new paradigm?

AU - Spyropoulos, A. C.

AU - Goldenberg, N. A.

AU - Kessler, C. M.

AU - Kittelson, J.

AU - Schulman, S.

AU - Turpie, A. G.G.

AU - Cutler, N. R.

AU - Hiatt, W. R.

AU - Halperin, J. L.

N1 - Funding Information: N.A.G. receives salary and research support in the form of a Career Development Award from the National Institutes of Health, National Heart, Lung and Blood Institute, and salary support through pharmaceutical industry sponsored research from CPC Clinical Research. Funding Information: W.R.H. is President of CPC Clinical Research. He receives support from grants provided by the National Institutes of Health and from the pharmaceutical industry for sponsored research initiatives, partial salary support through research grants provided to CPC Clinical Research and the University of Colorado, as well as fees from the U.S. Food and Drug Administration as a Special Government Employee for several advisory committees. He provides consulting services to the pharmaceutical industry though CPC Clinical Research. Current relationships include GlaxoSmithKline, sanofi‐aventis, Kowa, Portola, TheraVasc, AstraZeneca, Pluristem and Zona.

PY - 2012/12

Y1 - 2012/12

UR - https://www.scopus.com/pages/publications/84871044907

U2 - 10.1111/jth.12005

DO - 10.1111/jth.12005

M3 - Letter

C2 - 23006126

AN - SCOPUS:84871044907

SN - 1538-7933

VL - 10

SP - 2621

EP - 2624

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

IS - 12

ER -